Evidence map›Paper›PMID 37587362›Full record

ArticleAnnals of surgical oncology2023

Neoadjuvant Chemoimmunotherapy Increases Tumor Immune Lymphocytes Infiltration in Resectable Non-small Cell Lung Cancer.

Tianxiang Chen, Zhengqi Cao, Yingjia Sun, Jia Huang, Shengping Shen, Yueping Jin, Long Jiang, Fengcai Wen, Xiaochen Zhao, Ding Zhang and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Higher proximity of PD-L1Translational lung cancer research · 2026
    Article
  6. BAG3Frontiers in immunology · 2026
    Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Tianxiang Chen *Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.
Zhengqi Cao *Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.
Yingjia SunShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.
Jia HuangShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.
Shengping ShenShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.
Yueping JinShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.
Long JiangShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China.
Fengcai WenThe Medical Department, 3D Medicines Inc., Shanghai, China.
Xiaochen ZhaoThe Medical Department, 3D Medicines Inc., Shanghai, China.
Ding ZhangThe Medical Department, 3D Medicines Inc., Shanghai, China.
Yanan ChenThe Medical Department, 3D Medicines Inc., Shanghai, China.
Mengli HuangThe Medical Department, 3D Medicines Inc., Shanghai, China.
Hao ChenThe Medical Department, 3D Medicines Inc., Shanghai, China.
Shun LuShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China. shunlu@sjtu.edu.cn.
Ziming LiShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China. liziming1980@shsmu.edu.cn.
Shanghai Chest Hospital · CN

Funding

Guangdong Association of Clinical Trials (GACT)/Chinese Thoracic Oncology Group (CTONG) and Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer 2017B030314120Lian Yun Gang Shi Hui Lan Public Foundation HL-HS2020-65National Multi-disciplinary Treatment Project for Major Diseases 2020NMDTPNational Natural Science Foundation of China 82072564National Natural Science Foundation of China 82272679Program of Shanghai Academic Research Leader 22XD142280Project of Shanghai Natural Science Foundation 20ZR1452000Shanghai Chest Hospital Project of talent support 2018YNZYJ02Shanghai Municipal Health Commission 2022XD029Shanghai youth talent support program, Shanghai Chest Hospital Project of Collaborative Innovative Grant YJT20190209The Innovative Research Team of High-level Local Universities in Shanghai SHSMU-ZLCX20212302
6 · The paper itself

Abstract

backgroundNeoadjuvant chemoimmunotherapy treatment (NCIT) has achieved great success for non-small cell lung cancer (NSCLC); however, the intrinsic mechanism underlying this treatment remains unclear.

methodsThirty-two patients with stage IIA-IIIC NSCLC who underwent surgery after NCIT were included in this retrospective study. Multiplex immunofluorescence (mIF) staining and image analysis assays were performed on the samples collected before and after NCIT for each patient. RNA analyses was applied to confirm the mIF results.

resultsAmong the enrolled patients, 14 achieved major pathological response or pathological complete response (pCR) and were defined as the 'response' group, whereas 18 patients did not respond well to NCIT and were defined as the 'nonresponse' group. The results of the mIF assays revealed an overall increase in tumor immune lymphocytes (TILs) after NCIT in the stroma area (p = 0.03) rather than the tumor area (p = 0.86). The percentage of CD8+ T cells and tertiary lymphoid structure counts in both the response and nonresponse groups increased significantly after NCIT compared with before NCIT. CD3+ T cells and FOXP3+ cells decreased significantly in the response group but remained unchanged or increased in the nonresponse group. A comparison of the response and nonresponse groups showed that CD3, FOXP3+ and CD8+/PD-1+ cells before NCIT may serve as predictors of the response to neoadjuvant immunotherapy. The RNA analyses confirmed the mIF results that TILs were elevated after NCIT.

conclusionsThe infiltration of immune cells before NCIT was correlated with pathologic complete response, which enhanced the TILs as a promising predictor for selecting patients who were more likely to benefit from NCIT.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsForkhead Transcription FactorsHumansImmunotherapyLymphocytesLymphocytes, Tumor-InfiltratingNeoadjuvant TherapyRetrospective StudiesRNAForkhead Transcription FactorsRNAMultiplex immunofluorescenceNeoadjuvant immunotherapyNon-small cell lung cancerTumor lymphocytes infiltration

Identifiers

PMID37587362
OpenAlexW4385879083

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.